Cell and Gene Outsourcing
-
The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor Cells
1/17/2025
Explore how TARGATTĀ® gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.
-
CGMP-Validated RCL Assay Used For Release Testing Of Manufactured Viruses, Gene Mediated Cell Therapy Products
1/17/2025
Ensure the safety and efficacy of lentiviral-based therapies by addressing the risks of replication-competent lentiviruses (RCLs) through advanced monitoring and control strategies.
-
Successful Regulatory Submission Via The Trifecta Of Awesomeness
1/17/2025
Three essential elements contribute to a repeatable, adaptable regulatory submission process: strategic planning, team engagement, and properly leveraging team experience.
-
Building Frameworks To Support Complex Therapy Manufacturing
1/16/2025
To make its clinical product, CLBR001+SWI019, the Calibr-Skaggs Institute for Innovative Medicines relies on a complex network of contractors from around the globe.
-
Know Your Product, Know Your Path: A Primer On Advanced Therapy Development
1/16/2025
To prevent path-to-market setbacks, it is critical to develop a CMC strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.
-
Advance CGT With Scientific Insights Across Every Stage Of Development
1/14/2025
Partner with us to navigate the complexities of cell and gene therapy development, combining global infrastructure with personalized expertise to bring life-saving treatments to more patients.
-
Coordinating Global Capabilities To Support A Gene Therapy Targeting A Rare Neurodegenerative Disorder
1/14/2025
Advance your gene therapy program with expert support for IND submission, including GLP toxicology, biodistribution studies, and tailored CMC services.
-
Rapid And Robust Preclinical And Clinical Development Of CAR T-Cell Therapies
1/14/2025
Streamline CAR T-cell therapy development with integrated support for asset identification, IND submission, early-phase studies, and advanced real-time tracking solutions.
-
A Genome-Wide High-Throughput Gain-Of-Function Screen Identifies Novel Targets For Improved AAV9 Production
1/13/2025
Overcoming manufacturing challenges in AAV production is essential to improving quality, reducing costs, and ensuring safer, more accessible gene therapies for patients worldwide.
-
Manufacturing Of A Broad Range Of AAV Capsids Using Our Suspension Platform
1/13/2025
Yield and quality metrics vary significantly between AAV capsids, emphasizing the need for a modular manufacturing platform to address their unique requirements.